Sputtering Europe and Jittery China Add Bull Case for US Stocks

  • 📰 BNNBloomberg
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 50%

United States News News

United States United States Latest News,United States United States Headlines

Europe’s stagflation crisis and a property downturn in China are flashing a familiar message: for equity investors, there is no real alternative to the US stock market.

With four months left of 2023, returns on the S&P 500 boast about an eight percentage-point lead over the Stoxx Europe 600. The index is on course for its eighth year of outperformance in the past decade, as the artificial intelligence buzz overshadows economic recession fears and pricey valuations.

“It’s the economic resilience, the tailwinds from the weaker dollar, still fairly downbeat expectations on earnings. All of that plays in favor of the US,” Kettner added, in a reference to the view that dollar strength has finally topped out. Europe does have an edge on share valuations — on a price-to-earnings measure, the Stoxx 600 trades near a record low to the S&P 500. For some strategists such as David Groman at Citigroup Inc., that shows Europe is already pricing the bad news. Citi turned overweight on Europe in July and cut the US to neutral.

“I was talking with my team about what to buy in Europe as we are predominantly looking for growth and our conclusion was that there really wasn’t much indeed,” Domont added.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 83. in US
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Novo Nordisk is second most valuable company in Europe: ReportNovo Nordisk (NVO), who produces Ozempic and Wegovy, is the currently the second most valuable company in Europe, worth more than McDonald's (MCD) and Netflix (NFLX) combined, according to Chartr. Yahoo Finance Health Care Reporter Anjalee Khemlani discusses what's driving the company's value. 
Source: YahooFinanceCA - 🏆 47. / 63 Read more »

Novo Nordisk overtakes luxury group LVMH as Europe's most valuable companyLONDON (Reuters) - Danish drugmaker Novo Nordisk unseated LVMH as Europe's most valuable listed company on Friday, ending the French luxury group's ...
Source: SaltWire Network - 🏆 45. / 63 Read more »